OBiO Technology to be featured at American Society of Gene & Cell Therapy

OBiO Technology, a leading contract development and manufacturing organization for cell and gene therapy, is set to showcase its latest innovations at the American Society of Gene & Cell Therapy conference in Maryland, USA from May 7th to 11th. The company will present nine posters highlighting their groundbreaking achievements in the gene therapy domain.

Among the presentations are three self-developed patented achievements, four advancements in process optimization, and two cutting-edge technology introductions. These milestones demonstrate OBiO Technology’s commitment to enhancing vector yield and efficiency, refining therapeutic processes, and reducing production costs.

The innovative solutions offered by OBiO Technology provide reliable and cost-effective production methods for gene therapy, advancing clinical projects in gene and cell therapy. The company’s experts will be on hand to discuss how their viral vector platform accelerates development timelines, de-risks manufacturing, and ensures product quality at a lower cost.

“We are thrilled to showcase our latest achievements in gene and cell therapy at the ASGCT conference,” said Javier Jia Guo, Ph.D., CEO of OBiO Technology. “Our presentations exemplify our dedication to innovation and problem-solving in the industry, as well as our progress in enhancing efficiency and driving cost efficiencies.”

OBiO Technology’s state-of-the-art facility and expertise in vectorology studies, functional genomics, and process development ensure global supply excellence and support all stages of clinical and commercial manufacturing. The company’s mission to “Enable Gene Therapy for Better Lives” drives their commitment to delivering high-quality services worldwide.

With a focus on continuous improvement and technological advancement, OBiO Technology remains at the forefront of the gene and cell therapy industry, making a positive impact on populations worldwide.